Street Calls of the Week
Steven Leonard Chapman, CEO and President of Natera, Inc. (NASDAQ:NTRA), sold a total of 14,083 shares of common stock for approximately $3.7 million. The sales occurred in multiple transactions between September 30 and October 1, with prices ranging from $158.8434 to $162.0528. According to InvestingPro data, Natera currently has a market capitalization of $22.18 billion, with the stock showing significant volatility in recent trading.
The sales included 9,109 shares sold on September 30 at a price of $162.0528 per share. On October 1, Chapman sold 634 shares in a range of $158.18 to $159.07, 9,003 shares in a range of $159.2650 to $160.25, 3,976 shares in a range of $160.28 to $161.2075 and 470 shares in a range of $161.39 to $161.5750. The company maintains strong liquidity with a current ratio of 3.72 and has demonstrated impressive revenue growth of 44.38% over the last twelve months.
On September 29, Chapman also acquired 18,750 shares of Natera, Inc. common stock upon the vesting of restricted stock units. For deeper insights into Natera’s valuation and financial health metrics, including 11 additional ProTips and comprehensive analysis, check out the detailed research report available on InvestingPro.
In other recent news, Natera, Inc. has made significant strides in its clinical trials and research efforts. The company announced the enrollment of over 1,600 patients in its EXPAND trial, which aims to evaluate the Fetal Focus single gene noninvasive prenatal test. Additionally, Natera’s Signatera test has shown promising results in multiple studies, outperforming standard tumor markers in testicular cancer and demonstrating strong outcomes in monitoring uterine cancer. These findings were published in the Journal of Clinical Oncology - Precision Oncology.
In terms of analyst evaluations, Wells Fargo resumed coverage of Natera with an Equal Weight rating, highlighting the company’s robust position in cell-free DNA testing technology. Meanwhile, Piper Sandler reiterated an Overweight rating for Natera, following positive results from the IMvigor011 trial, which is notable for its advancements in Minimal Residual Disease testing. These developments underscore Natera’s ongoing efforts in expanding its testing capabilities across various medical fields.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.